ストックスクリーナーアプリを入手
52.70
8.68%
-5.01
アフターアワーズ：
52.69
-0.01
-0.02%
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
Arrowhead (ARWR) Shares Drop Over 8% in Recent Trading - GuruFocus
Is Arrowhead Pharmaceuticals Inc a good long term investmentRisk-Reward Ratio Analysis & Minimal Capital Trading - earlytimes.in
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Arrowhead: Gains Make Mockery Of My Sell CallBut Jury May Still Be Out (Rating Upgrade) - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (HDP1.F) stock price, news, quote and history - Yahoo Finance UK
Arrowhead Pharmaceuticals Reports Transformative Year-End Results - MSN
Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval - Finviz
Morgan Stanley Maintains Arrowhead Pharmaceuticals (ARWR) Equal-Weight Recommendation - MSN
Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy - Yahoo Finance
Arrowhead Pharmaceuticals Hits Day High with 9.42% Surge in Stock Price - Markets Mojo
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity - TipRanks
10 Big Names Feasting on Gains Ahead of Thanksgiving - Insider Monkey
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today - MSN
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Arrowhead Pharmaceuticals’ Earnings Call Highlights FDA Approval and Strong Financials - TipRanks
Arrowhead Pharmaceuticals Reports Record Revenue and FDA Approvals - StocksToTrade
Arrowhead’s Triumph: A New Dawn? - timothysykes.com
How (ARWR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Arrowhead outlines REDEMPLO expansion with $60,000 annual price and expects top-line SHASTA-3/4 data in Q3 2026 - MSN
Arrowhead Pharmaceuticals: Hold Rating Amid Redemplo Launch and Financial Stability - TipRanks
Arrowhead (ARWR) Shares Surge Over 23% - GuruFocus
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Arrowhead Pharmaceuticals Takes Significant Strides with FDA Approval Boosting Market Confidence - timothysykes.com
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On WednesdayArrowhead Pharma (NASDAQ:ARWR), Duolingo (NASDAQ:DUOL) - Benzinga
Morgan Stanley Raises Price Target for ARWR to $48.00 | ARWR Sto - GuruFocus
Arrowhead (ARWR) Shares Surge by 9% - GuruFocus
Arrowhead Pharmaceuticals Hits New 52-Week High of $46.89 - Markets Mojo
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2025 Earnings Call Transcript - Insider Monkey
Arrowhead Pharmaceuticals : ARWR FQ4 2025 Script Final - MarketScreener
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results - BioSpace
Earnings call transcript: Arrowhead Pharmaceuticals Q4 2025 sees stock surge - Investing.com Australia
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Achieves FDA Approval for REDEM - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... - Yahoo Finance
Earnings Call Summary | Arrowhead Pharmaceuticals(ARWR.US) Q4 2025 Earnings Conference - 富途牛牛
Why Shares in Arcutis Biotherapeutics Surged Again This Week - AOL.com
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership Pasadena-based Arrowhead Pharmaceuticals Inc., based in Pasadena, announced it has earned a $200 million milestone payment from Sarepta Therapeutics afte - facebook.com
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript - AOL.com
Arrowhead Pharmaceuticals (ARWR) Stock: Soars Following Strong Financial Performance and FDA Approval - parameter.io
Arrowhead Pharmaceuticals (ARWR) Surpasses Revenue Estimates wit - GuruFocus
Arrowhead Pharmaceuticals Fiscal-Year Loss Narrows, Revenue Rises - MarketScreener
Arrowhead (ARWR) Surpasses Revenue Expectations with FDA Approva - GuruFocus
Arrowhead reports FY25 EPS (1c), consensus (3c) - TipRanks
ARROWHEAD PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - MarketScreener
[8-K] ARROWHEAD PHARMACEUTICALS, INC. Reports Material Event | ARWR SEC FilingForm 8-K - Stock Titan
Arrowhead Pharmaceuticals Hits New 52-Week High of $44.80 - Markets Mojo
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Arrowhead Pharmaceuticals FQ4 2025 Earnings Preview - MSN
ARWR Stock: Arrowhead Pharmaceuticals Hits New High as FDA Approval and Q4 Earnings Converge - ts2.tech
Arrowhead Pharmaceuticals (ARWR) Awaits FQ4 Earnings Amid Recent FDA Approval - GuruFocus
Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target - Stocktwits
Arrowhead Pharmaceuticals at TD Cowen Summit: Strategic Advances in Obesity - Investing.com
Arrowhead Pharmaceuticals stock hits 52-week high at $43.70 By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals stock hits 52-week high at $43.70 - Investing.com
A Look Ahead: Arrowhead Pharma's Earnings Forecast - Benzinga
0.45%
1.13%
大文字化:
|
ボリューム (24 時間):